CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1 Ascending Dose And Parallel Group Trial To Establish The Safety, Tolerability And Pharmacokinetic Profile of Multiple Intravitreous Injections of ARC1905 (Anti-C5 Aptamer) Given In Combination With Multiple Doses of Lucentis® 0.5 mg/Eye In Subjects With Neovascular Age-Related Macular Degeneration

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT00709527
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:26:45.753418+00:00
Published At: 2025-03-10T00:00:00+00:00
Record Updated At: 2025-03-10
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Neovascular Age-Related Macular Degeneration"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-03-10"
protocolSection.identificationModule.nctId: "NCT00709527"
protocolSection.identificationModule.officialTitle: "A Phase 1 Ascending Dose And Parallel Group Trial To Establish The Safety, Tolerability And Pharmacokinetic Profile of Multiple Intravitreous Injections of ARC1905 (Anti-C5 Aptamer) Given In Combination With Multiple Doses of Lucentis\u00ae 0.5 mg/Eye In Subjects With Neovascular Age-Related Macular Degeneration"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.